A pair of Korean companies have teamed up to buy stem cell manufacturing facilities and other assets of a failed U.S. biotech.
Drug wholesaler McKesson was lashed in an FDA warning letter for shipments in which opioids had been replaced by OTC drugs.
Progenics last year picked up an FDA approval for its orphan radiotherapeutic. Now it has picked up a manufacturing facility to produce it in.
Immunomedics says it will meet with the FDA to discuss the CRL it got for manufacturing, while Teva has a new union agreement in place.
Dr. Reddy’s reported that its formulation plant in Bachupally, India, has been cited by the FDA with 11 violations.
The global recall of valsartan has now extended to Pfizer and to Japan, via Mylan and India.
Despite some additional incentives offered by Pfizer, workers at two plants in Ireland rejected a pension switch and voted for a work action.
Lonza and Portola are hard at work; the FDA goes after a compounder; and an Indian biotech opts for continuous manufacturing.
Tris Pharma, which first recalled potentially harmful infants' ibuprofen in December, is adding lots to the recall.
Healthcare management company Premier has set up a new subsidiary to focus on helping providers with drug shortages.
